Back to Authors

Barwise, Amelia K

0000-0001-9267-1298

Mayo Clinic

Department of Quantitative Health Sciences, Biomedical Ethics Research Program, Mayo Clinic, Rochester, Minnesota, USA.

Citations 52

Coadministration of Liposomal Amphotericin B and Contrast Medium Does Not Increase Risk of Kidney Injury
O’Horo, John C. , Osmon, Douglas R. , Saleh, Omar Abu , Marcelin, Jasmine R , Gharaibeh, Kamel A. , Hamadah, Abdurrahman , Barwise, Amelia , Kayhart, Bryce M., McDonald, Robert J. , McDonald, Jennifer S. , Leung, Nelson , Marcelin, Jasmine , Barwise, Amelia K , O'Horo, John C

Antimicrobial Agents and Chemotherapy | May 23, 2017 | Volume: 61 | Issue: 8 | Pages: No page available

10.1128/aac.00323-17 Get It

ABSTRACT Intravenous radiographic contrast medium and amphotericin B are commonly required in the care of patients with fungal infections. Both interventions have proposed nephrotoxicity through similar mechanisms. We systematically examined patients who received coadministration of liposomal amphotericin B (AmBisome; GE Healthcare) and intravenous contrast medium within a 24-h period and compared the results for those patients with the results for patients who underwent non-contrast medium studies. We found 114 cases and 85 controls during our study period. Overall, no increased risk of renal injury was seen with coadministration of these 2 agents. Adjustment for age, baseline kidney function, and other clinical factors through propensity score adjustment did not change this result. Our observations suggest that, when clinically indicated, coadministration of contrast medium and liposomal amphotericin B does not present excess risk compared with that from the administration of liposomal amphotericin B alone.
Medicaid Expansion and Implications for Cancer Disparities
Barwise, Amelia , Barwise, Amelia K

American Journal of Public Health | May 6, 2016 | Volume: 106 | Issue: 6 | Pages: e8-e8

10.2105/ajph.2016.303105 Get It